Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Product
Deals
Articles
BioCentury
|
Aug 14, 2019
Financial News
D&D raises $137M to fund inflammation tech out of JHU
...is an associate professor of radiology at Johns Hopkins School of Medicine. Theraly's lead asset,
TLY012
...
Read More
BioCentury
|
Mar 19, 2019
Distillery Therapeutics
Agonizing TNFRSF10B for scleroderma
...a control IgG. Also in the model and in a genetic mouse model of scleroderma,
TLY012
...
...TNFRSF10B agonists in combination with other antifibrotic agents in the models. Theraly Fibrosis Inc. has
TLY012
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page